Target intelligence / Profile preview

Dopaminergic nervous system

Molecular classification
Other (represents a neural system, not a single molecular entity), Comprised of multiple receptors (G protein-coupled receptor), transporters, enzymes[1][2][3]
01

Overview

"Dopaminergic nervous system" is not a canonical name for a single molecule or receptor; rather, it refers to the entire system of neurons and receptors that utilize dopamine as a neurotransmitter. Typically, therapeutic targets in this system are individual dopamine receptors (such as D1, D2, D3, D4, D5) or dopamine transporter proteins, not the whole system as a single target[1][3]. The dopaminergic nervous system encompasses the network of neurons, receptors, and molecular pathways that utilize dopamine for neurotransmission. It is essential for motor control, reward processing, cognition, and mood regulation. Key molecular targets within this system include various dopamine receptors (D1–D5, all G protein-coupled receptors), dopamine transporter (DAT), and enzymes involved in dopamine synthesis and metabolism. Dysregulation of this system is implicated in Parkinson's disease, schizophrenia, mood disorders, and addiction[1][3][4]. As an umbrella term, it does not correspond to a single canonical molecular target. For structured data, specific entities such as "Dopamine D2 receptor" should be used instead, making this entry incorrect for a canonical single-molecule target in pharmacology.

Other names
Dopaminergic systemCentral dopaminergic pathwayDopamine system
02

Mechanism of action

Agonism/antagonism of dopamine receptors[3]; Modulation of dopamine release or reuptake[3]

03

Biological functions

Signal transductionNeurotransmissionMotor controlReward processingLearning and memory[3][4]
04

Disease associations

Neurodegenerative disease (e.g., Parkinson's disease)Psychiatric disorders (e.g., schizophrenia, depression)Substance use disordersOther neurological diseases[3]
05

Safety considerations

Movement disorders (extrapyramidal symptoms, tardive dyskinesia)Psychiatric symptoms (psychosis, mood disturbances)Cardiovascular effects (arrhythmias, orthostatic hypotension)[3]
06

Interacting drugs

L-DOPA (levodopa)

3 more in the full profile.

07

Biomarkers

Dopamine levels (CSF, blood)Imaging ligands (e.g., DAT SPECT/PET)Receptor density mapping (PET ligands)[3]

Beyond the preview

Go deeper on Dopaminergic nervous system.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dopaminergic nervous system.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call